Dynavax Technologies

Dynavax Technologies is the most under-followed positive-cash-flow specialty vaccine company in US small-cap healthcare, and the equity story is hiding in plain sight behind a single product narrative: HEPLISAV-B, the only 2-dose adult hepatitis B vaccine on the market, in a category that for decades was a sleepy GSK and Merck duopoly with the legacy 3-dose Engerix-B and Recombivax HB regimens. HEPLISAV-B received FDA approval in 2017, and by 2022 the CDC ACIP voted a universal adult Hep B recommendation for ages 19 to 59, a regulatory unlock that effectively re-priced the entire adult Hep B vaccine TAM upward and gave Dynavax — as the only manufacturer with a 2-dose-compliant regimen — a structural market share advantage.

The numerical evidence of the franchise win is in the print: HEPLISAV-B held an estimated 45%+ share of the US adult Hep B vaccine market by 2025, up from low single digits at launch. Revenue grew 17.7% year-over-year to $330 million on a 61.6% gross margin, operating margin was positive 24.8%, and free cash flow generated was $51 million — these are real cash-flow characteristics on a single product, not a clinical-stage burn story. The 405-employee organization is a deliberately lean commercial vaccine operation, and the post-2024 leadership transition (long-serving CEO Ryan Spencer continuing) has kept the operational discipline tight.

The 2020-2022 COVID era windfall — CpG 1018 adjuvant supply agreements with Clover, Biological E, and Valneva — provided several hundred million dollars of one-time cash that built the current ~$700+ million treasury. That cash war chest has funded an aggressive buyback program (Dynavax has repurchased a meaningful percentage of float since 2023) and provides the optionality for either bolt-on acquisitions, a strategic biodefense pipeline expansion via the BARDA-partnered rF1V plague vaccine, or, increasingly likely, a strategic sale to a Big-Pharma vaccine player.

The 13% short interest reflects the bear thesis that HEPLISAV-B growth is decelerating as the easy ACIP-driven share grab is now in the rearview, while the pipeline beyond HEPLISAV-B (shingles Z-1018, plague rF1V) is years away from commercial contribution. That is a defensible thesis on a 12-month view but underweights the strategic-value argument that is increasingly the real driver of equity returns here.

Dynavax has long had quiet but substantial institutional support from specialist healthcare funds that recognize the cash-flow profile is mispriced relative to clinical-stage vaccine peers. Bain Capital Life Sciences and RA Capital have appeared as historical 13F holders. Vanguard and BlackRock index ownership is large in absolute terms but reflects passive allocation rather than thesis-driven conviction. The more interesting smart-money signal is the absence of any meaningful insider selling through 2024-2025 — at the 52-week low of essentially $0 (the formal low data point) and through the recent recovery to $15.50, Spencer and the C-suite have not been distributing despite years of vested option overhangs.

The strategic-buyer pattern is the more important institutional signal. Sanofi has a long-standing vaccine franchise (Pasteur) and has publicly stated interest in expanding adult vaccine offerings; GSK already has Engerix-B but is increasingly under generic-Hep-B competitive pressure and could rationalize portfolio overlap by acquisition; Pfizer, post-COVID-cliff, is actively looking for accretive specialty acquisitions in the $1-3 billion range. The fact that Dynavax has not been acquired at the depressed sub-$2 billion market cap reflects either active negotiations in progress (typical 6-18 month timeline) or a board view that the standalone trajectory provides better value through 2027.

Short interest at 13.19% is the contra-indicator. Some of that is event-arbitrage positioning (post-buyback-completion thesis), but a meaningful component is structural skepticism about HEPLISAV durability post-share-grab phase. Watch for short-cover acceleration if any strategic process leaks.

At a $1.8 billion market cap and roughly $700 million net cash, Dynavax enterprise value is approximately $1.1 billion against trailing revenue of $330 million — an EV-to-Sales multiple of 3.3x. Forward P/E of 46.97 reflects a modest expected earnings ramp as the buyback compounds and the pipeline R&D investment phase continues. The trailing P/E is not meaningful given GAAP accounting for the historical CpG inventory adjustments.

The cleaner valuation framework is EV-to-EBITDA or EV-to-free-cash-flow. On $80-90 million of operating cash flow excluding R&D pipeline investment, the EV-to-FCF multiple is approximately 12-13x — which would be cheap for a branded, growing, single-product vaccine franchise with strategic optionality. For comparison, Heron Therapeutics, Halozyme, and similar specialty pharmaceutical franchises with comparable revenue and growth profiles trade closer to 15-20x EV-to-FCF, suggesting Dynavax is materially undervalued on operating cash-flow comp.

The strategic-buyer math is even more dramatic. A Sanofi, GSK, or Pfizer acquisition at typical specialty pharma EV-to-Sales multiples of 5-7x would imply $1.65-2.3 billion enterprise value or roughly $20-25 per share in a take-out scenario — a 30-60% premium to current trading. The fact that this multiple gap persists despite the obvious strategic logic suggests either the strategic process is in progress or the board is holding out for a higher price.

1. Q3 2026: HEPLISAV-B 2026 full-year revenue and 2027 guidance — confirms or breaks the deceleration narrative; consensus modeling assumes mid-teens growth, an upside surprise re-rates the franchise multiple
2. H2 2026: Potential strategic-sale announcement or formal strategic review disclosure — sustained sub-$20 trading despite cash-flow profile increases pressure on the board to monetize
3. FY 2026: rF1V Phase 2 plague vaccine readout and BARDA contract progression — provides biodefense-stockpile revenue visibility that diversifies away from HEPLISAV concentration

DVAX is the quietest 3.3x EV-to-Sales single-product vaccine franchise in US small cap, and the equity setup is meaningfully more interesting than the price action suggests. The HEPLISAV deceleration narrative is real but the cash-flow profile and strategic value are not getting credit from the screen-driven flows. At a sub-$2 billion market cap with $700 million in net cash and $50+ million in annual free cash flow even after R&D investment, the downside is limited to the cash floor plus residual HEPLISAV equity value — which is itself probably $1+ billion on conservative assumptions.

What I think the market is mispricing is the strategic-buyer probability. A Sanofi, GSK, or Pfizer acquisition at typical specialty pharma multiples implies $20-25 per share. The current $15.50 print embeds essentially zero strategic-acquisition probability, which feels wrong given the obvious portfolio logic and the active Big Pharma M&A environment. I do not think DVAX is a screaming buy at any price, but I think the asymmetry of buying near $15 — with a clear floor at $12 and a strategic ceiling at $25 — is structurally attractive for size-modest patient capital.